JP7860224B2 - 投薬レジーム - Google Patents

投薬レジーム

Info

Publication number
JP7860224B2
JP7860224B2 JP2024513893A JP2024513893A JP7860224B2 JP 7860224 B2 JP7860224 B2 JP 7860224B2 JP 2024513893 A JP2024513893 A JP 2024513893A JP 2024513893 A JP2024513893 A JP 2024513893A JP 7860224 B2 JP7860224 B2 JP 7860224B2
Authority
JP
Japan
Prior art keywords
peg3
carboxy
kek
isoglu
aib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024513893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533153A5 (enExample
JP2024533153A (ja
Inventor
ミゲル アスジャール エーヤスナプ
Original Assignee
ジーランド ファーマ エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーランド ファーマ エー／エス filed Critical ジーランド ファーマ エー／エス
Publication of JP2024533153A publication Critical patent/JP2024533153A/ja
Publication of JP2024533153A5 publication Critical patent/JP2024533153A5/ja
Application granted granted Critical
Publication of JP7860224B2 publication Critical patent/JP7860224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024513893A 2021-09-03 2022-09-02 投薬レジーム Active JP7860224B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21194879.9 2021-09-03
EP21194879 2021-09-03
EP22160234.5 2022-03-04
EP22160234 2022-03-04
PCT/EP2022/074420 WO2023031380A1 (en) 2021-09-03 2022-09-02 Dosage regime

Publications (3)

Publication Number Publication Date
JP2024533153A JP2024533153A (ja) 2024-09-12
JP2024533153A5 JP2024533153A5 (enExample) 2024-10-09
JP7860224B2 true JP7860224B2 (ja) 2026-05-15

Family

ID=84272918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513893A Active JP7860224B2 (ja) 2021-09-03 2022-09-02 投薬レジーム

Country Status (11)

Country Link
US (1) US20250073311A1 (enExample)
EP (1) EP4392054A1 (enExample)
JP (1) JP7860224B2 (enExample)
KR (1) KR20240058121A (enExample)
AU (1) AU2022339044A1 (enExample)
CA (1) CA3228429A1 (enExample)
CL (1) CL2024000647A1 (enExample)
IL (1) IL311166A (enExample)
MX (1) MX2024002600A (enExample)
TW (1) TW202315882A (enExample)
WO (1) WO2023031380A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025248124A1 (en) 2024-05-31 2025-12-04 Zealand Pharma A/S Dapiglutide for use in treating a sub-group of subjects
WO2026052859A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide
WO2026052861A1 (en) 2024-09-09 2026-03-12 Zealand Pharma A/S Treatment with dapiglutide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525890A (ja) 2016-12-09 2019-09-12 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
JP2020500890A (ja) 2016-12-09 2020-01-16 ジーランド・ファーマ・ア／エス Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2018104558A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4126003A1 (en) * 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
IL301891A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
AU2021399904B2 (en) * 2020-12-16 2024-09-05 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
TWI921427B (zh) * 2020-12-16 2026-04-11 丹麥商西蘭製藥公司 Glp-1/glp-2雙重促效劑之醫藥組合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525890A (ja) 2016-12-09 2019-09-12 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
JP2020500890A (ja) 2016-12-09 2020-01-16 ジーランド・ファーマ・ア／エス Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト

Also Published As

Publication number Publication date
TW202315882A (zh) 2023-04-16
EP4392054A1 (en) 2024-07-03
CL2024000647A1 (es) 2024-09-13
KR20240058121A (ko) 2024-05-03
IL311166A (en) 2024-04-01
US20250073311A1 (en) 2025-03-06
CA3228429A1 (en) 2023-03-09
AU2022339044A1 (en) 2024-03-14
WO2023031380A1 (en) 2023-03-09
WO2023031380A9 (en) 2024-02-22
MX2024002600A (es) 2024-03-22
JP2024533153A (ja) 2024-09-12

Similar Documents

Publication Publication Date Title
US11395847B2 (en) Acylated GLP-1/GLP-2 dual agonists
EP3551652B1 (en) Glp-1/glp-2 dual agonists
TWI670281B (zh) Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
WO2018104558A1 (en) Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) Acylated glp-1/glp-2 dual agonists
US20250073311A1 (en) Dosage regime
CN117979986A (zh) 给药方案
CA3043151C (en) Acylated glp-1/glp-2 dual agonists
HK40111792A (en) Acylated glp-1/glp-2 dual agonists
HK40007709B (en) Acylated glp-1/glp-2 dual agonists
HK40007709A (en) Acylated glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260430

R150 Certificate of patent or registration of utility model

Ref document number: 7860224

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150